SS
Stephen L Sabba
Director

Stephen L Sabba insider trades: Ligand Pharmaceuticals (LGND) stock buys and sales

Director, Ligand Pharmaceuticals Last trade Jun 16, 2026 42 Form 4 filings
$1.2M
Sold, last 12 months
3 sales
$0
Bought, last 12 months
0 buys
12
Open-market trades
since 2011
4
Companies
last trade 2026

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Stephen reports to the SEC

Open-market buys and sales

12 trades reported on SEC Form 4, newest first

DateStockTypeValue
Jun 16, 2026LGND↓ Sell$545K
Mar 23, 2026LGND↓ Sell$208K
Mar 3, 2026LGND↓ Sell$410K
Mar 5, 2024LGND↓ Sell$141K
May 10, 2023LGND↓ Sell$494K
Feb 9, 2021LGND↓ Sell$3.1M
Jul 31, 2019LGND↓ Sell$386K
Sep 4, 2018LGND↓ Sell$1.3M
Mar 12, 2018LGND↓ Sell$112K
Dec 20, 2017LGND↓ Sell$127K
Feb 27, 2014LGND↓ Sell$36K
Nov 14, 2011LGND↑ Buy$23K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

Other LGND insiders

Open-market trades in the last 12 months

About Stephen L Sabba's insider trades

Stephen L Sabba is a director at Ligand Pharmaceuticals (LGND). Since Nov 14, 2011, Stephen has reported 1 open-market purchase worth $23K and 11 sales worth $6.8M on SEC Form 4. In the last 12 months: 3 sales ($1.2M).

Their filings also include grants and awards (26 filings), option exercises (10 filings), other transactions (1 filing), shares returned to the company (1 filing). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every LGND insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.